Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen

PLoS Medicine - United States
doi 10.1371/journal.pmed.0040090
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

P2-033Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel Dose Dense in Stage III Breast Cancer

Annals of Oncology
MedicineOncologyHematology
2018English

Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer

New England Journal of Medicine
Medicine
2006English

Epirubicin/Cyclophosphamide Followed by Docetaxel as Primary Systemic Therapy in Breast Cancer

Annals of Cancer Research and Therapy
Cancer ResearchOncologyPharmacology
2014English

Are Basal-Like and Non-Basal-Like Triple-Negative Breast Cancers Really Different?

Journal of Oncology
Oncology
2020English

MA16.04 Clinical and Molecular Characteristics of EGFR Mutant Lung Cancers With Concurrent TP53 and RB1 Mutations

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

A Feasibility Study of Bevacizumab Plus Dose-Dense Doxorubicin-Cyclophosphamide (AC) Followed by Nanoparticle Albumin-Bound Paclitaxel in Early-Stage Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2011English

Ambra1 Modulates the Sensitivity of Breast Cancer Cells to Epirubicin by Regulating Autophagy via ATG12

Cancer Science
Cancer ResearchMedicineOncology
2018English

Gene Expression Profiling Shows Medullary Breast Cancer Is a Subgroup of Basal Breast Cancers

Cancer Research
Cancer ResearchOncology
2006English

Feasibility and Safety of a Reduced Duration of Therapy of Colony-Stimulating Factor in a Dose-Dense Regimen

Supportive Care in Cancer
Oncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy